drugset / Trial / NCT05518357
LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, single-arm, open-label phase I clinical study to determine the safety and efficacy of LILRB4 STAR-T cells in relapsed/refractory acute myeloid leukemia subjects.
Timeline
- Start
- 2022-06-24
- Primary completion
- 2022-11-15
- Completion
- 2022-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LILRB4 STAR-T | Unknown | 1e+06 cells/kg | Intravenous |
| Subject | LILRB4 STAR-T | Unknown | 3e+06 cells/kg | Intravenous |
| Subject | LILRB4 STAR-T | Unknown | 1e+07 cells/kg | Intravenous |